Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

NCT04593927

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)

Interventions: Mayzent

Countries: Japan

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

Eligibility overview

Sex: ALL

Age: — to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients prescribed Mayzent for prevention of relapses and delay of progression of physical disability in secondary progressive multiple sclerosis

Exclusion Criteria:

\-
Locations (174)
  • Anjo, Aichi-ken, Japan
  • Hekinan, Aichi-ken, Japan
  • Ichinomiya, Aichi-ken, Japan
  • Kariya, Aichi-ken, Japan
  • Kasugai, Aichi-ken, Japan
  • Nagakute, Aichi-ken, Japan
  • Nagoya, Aichi-ken, Japan
  • Nagoya, Aichi-ken, Japan
  • Nagoya, Aichi-ken, Japan
  • Nagoya, Aichi-ken, Japan
  • Nagoya, Aichi-ken, Japan
  • Seto, Aichi-ken, Japan
  • Hachinohe, Aomori, Japan
  • Hirosaki, Aomori, Japan
  • Ichihara, Chiba, Japan
  • Ichikawa, Chiba, Japan
  • Yachiyo, Chiba, Japan
  • Tōon, Ehime, Japan
  • Fukuoka, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Gifu, Gifu, Japan
  • Gifu, Gifu, Japan
  • Isesaki, Gunma, Japan
  • Maebashi, Gunma, Japan
  • Maebashi, Gunma, Japan
  • Ōta, Gunma, Japan
  • Fukuyama, Hiroshima, Japan
  • + 144 more on CT.gov